Articles Tagged With: fezolinetant
-
Nonhormonal Treatment for Menopausal Vasomotor Symptoms: A Phase III Study of Fezolinetant
More than 500 women with moderate to severe menopausal vasomotor symptoms received either 45 mg of fezolinetant, 30 mg fezolinetant, or placebo. Both fezolinetant doses significantly reduced the frequency and severity of menopausal symptoms at four and 12 weeks of treatment vs. placebo.
-
Nonhormonal Treatment for Menopausal Vasomotor Symptoms: A Phase III Study of Fezolinetant
In this multinational, randomized, double blind, placebo-controlled trial, 522 women with moderate to severe menopausal vasomotor symptoms received either 45 mg of fezolinetant, 30 mg fezolinetant, or placebo. Both fezolinetant doses significantly reduced the frequency and severity of menopausal symptoms at four and 12 weeks of treatment as compared with placebo.
-
Fezolinetant Tablets (Veozah)
Fezolinetant can be prescribed to treat moderate-to-severe vasomotor symptoms caused by menopause.
-
Oral Medication to Treat ‘Hot Flashes’ Could Be Available Soon
The FDA has approved the first neurokinin 3 receptor antagonist to alleviate symptoms associated with moderate to severe vasomotor symptoms caused by menopause.
-
Fezolinetant Shows Positive Response in Vasomotor Symptoms Associated with Menopause
A phase 2b trial using seven dosing regimens of a novel neurokinin-3 receptor antagonist, fezolinetant, shows statistically significant improvement in vasomotor symptoms vs. placebo in postmenopausal women.